N4 Pharma PLC Oral application update (8746M)

TIDMN4P

RNS Number : 8746M

N4 Pharma PLC

17 January 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

Oral application update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, provides an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the oral delivery of Nuvec(R) loaded with DNA.

The Company has now completed two in vivo studies demonstrating that Nuvec loaded with OVA m-cherry DNA and encapsulated within an acid protective polymer can be dosed orally, penetrate the mucus layer and successfully express the OVA m-cherry locally in the intestine epithelial cells.

In the first study Nuvec(R) was formulated together with the OVA and the whole formulation was coated with the polymer as a capsule. In the second study the nanoparticles, once loaded with OVA, were individually encapsulated with the polymer and administered via an oral gavage.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"These studies are at an early stage in the development of an oral application, but show the versatility of Nuvec both in terms of its ease of formulation and application in a wide number of areas. Having successfully demonstrated Nuvec can be administered orally and locally transfect cells in the intestine, the next step is to investigate what the most suitable medical application might be for this delivery method.

We are greatly encouraged by these early results and look forward to continuing the work in this area, whilst continuing with our ongoing siRNA work."

Enquiries:

 
 N4 Pharma Plc                           Via Scott PR 
  Nigel Theobald, CEO                     Tel +44 1477 539539 
  Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP          Tel: +44 (0)20 3470 
  Nominated Adviser and Joint Broker      0470 
  Matthew Johnson/Kasia Brzozowska 
  (Corporate Finance) 
  Vadim Alexandre/Rob Rees (Corporate 
  Broking) 
 Turner Pope Investments (TPI) Limited    Tel: +44 (0)20 3657 
  Joint Broker                             0050 
  Andy Thacker

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDZZGMMDVZGFZM

(END) Dow Jones Newswires

January 17, 2023 02:00 ET (07:00 GMT)

N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024